title: Critical roles of hydrophobicity and orientation of side chains for inactivation of sarcoplasmic reticulum Ca2+-ATPase with thapsigargin and thapsigargin analogs.
abstract: Thapsigargin (Tg), a specific inhibitor of sarco/endoplasmic Ca(2+)-ATPases (SERCA), binds with high affinity to the E2 conformation of these ATPases. SERCA inhibition leads to elevated calcium levels in the cytoplasm, which in turn induces apoptosis. We present x-ray crystallographic and intrinsic fluorescence data to show how Tg and chemical analogs of the compound with modified or removed side chains bind to isolated SERCA 1a membranes. This occurs by uptake via the membrane lipid followed by insertion into a resident intramembranous binding site with few adaptative changes. Our binding data indicate that a balanced hydrophobicity and accurate positioning of the side chains, provided by the central guaianolide ring structure, defines a pharmacophore of Tg that governs both high affinity and access to the protein-binding site. Tg analogs substituted with long linkers at O-8 extend from the binding site between transmembrane segments to the putative N-terminal Ca(2+) entry pathway. The long chain analogs provide a rational basis for the localization of the linker, the presence of which is necessary for enabling prostate-specific antigen to cleave peptide-conjugated prodrugs targeting SERCA of cancer cells (Denmeade, S. R., Jakobsen, C. M., Janssen, S., Khan, S. R., Garrett, E. S., Lilja, H., Christensen, S. B., and Isaacs, J. T. (2003) J. Natl. Cancer Inst. 95, 990-1000). Our study demonstrates the usefulness of a simple in vitro system to test and direct development toward the formulation of new Tg derivatives with improved properties for SERCA targeting. Finally, we propose that the Tg binding pocket may be a regulatory site that, for example, is sensitive to cholesterol.
authors.affiliation: Centre for Membrane Pumps in Cells and Disease-PUMPKIN, Danish National Research Foundation, Denmark.
authors.forename: Anne-Marie L
authors.initials: AM
authors.lastname: Winther
authors.forename: Huizhen
authors.initials: H
authors.lastname: Liu
authors.forename: Yonathan
authors.initials: Y
authors.lastname: Sonntag
authors.forename: Claus
authors.initials: C
authors.lastname: Olesen
authors.forename: Marc
authors.initials: M
authors.lastname: le Maire
authors.forename: Helmer
authors.initials: H
authors.lastname: Soehoel
authors.forename: Carl-Erik
authors.initials: CE
authors.lastname: Olsen
authors.forename: S Brøgger
authors.initials: SB
authors.lastname: Christensen
authors.forename: Poul
authors.initials: P
authors.lastname: Nissen
authors.forename: Jesper V
authors.initials: JV
authors.lastname: Møller
mesh_terms: D018360:Crystallography, X-Ray; D016503:Drug Delivery Systems; D004791:Enzyme Inhibitors / Q000737:chemistry*; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D009369:Neoplasms / Q000188:drug therapy; D011485:Protein Binding / Q000187:drug effects; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D019284:Thapsigargin / Q000031:analogs & derivatives* / Q000737:chemistry*
chemical_list: D004791:Enzyme Inhibitors; D019284:Thapsigargin; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; C506943:ATP2A1 protein, human